Navigation Links
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
Date:9/13/2007

adding to our strong pipeline in this therapeutic area."

About glucagon receptor (GCGR), target of ISIS 325568

Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose. In Type 2 diabetes, unopposed action of glucagon can lead to increased blood glucose levels. Reducing the expression of liver GCGR using antisense inhibitors, and thereby reducing excessive liver glucose production, is expected to lower blood glucose levels and help control Type 2 diabetes. In preclinical studies, antisense inhibitors of GCGR led to improved glucose control and reduced levels of blood triglycerides without producing hypoglycemia. In addition, treatment with ISIS 325568 led to an increase in circulating glucagon-like peptide, or GLP-1, which is a hormone that helps to preserve pancreatic function, thereby enhancing insulin secretion.

About glucocorticoid receptor (GCCR), target of ISIS 377131

Glucocorticoid hormones have a variety of effects throughout the body, including promoting liver glucose production and fat storage. Although inhibition of GCCR has long been recognized as an attractive strategy for development of therapeutics for Type 2 diabetes, the side effects associated with systemic GCCR inhibition have challenged development of traditional drugs. Antisense inhibitors of GCCR take advantage of the unique tissue distribution of oligonucleotides that allows the antisense drugs to antagonize glucocortocoid action primarily in liver and fat tissue. Notably, antisense drugs do not reduce GCCR expression in the central nervous system or adrenal glands -- inhibition of GCCR expression in these two organs can lead to systemic side effects. In preclinical studies, Isis has shown that ISIS 377131 has a broad therapeutic profile that includes reduction of blood glucose levels, a dramatic and favorable effect on lipid levels including cholesterol and triglycerides, and a reduction in body fat.

Conference Call'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
3. Software company enters health space with RFID solutions on hold
4. Lucigen Corp. enters global licensing agreement
5. Call centers and customer service: The good, the bad, and the clueless
6. GE Healthcare enters agreement with Canadian health authority
7. Data centers: Buyers beware of over-hyped facilities
8. Data centers: Blowing smoke and raising red flags
9. Prodesse enters patent agreement with Roche
10. UW-Madison enters Kauffman grant competition
11. Applied Technology Centers to aid printing and manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), a ... , today announced that the Company will report results for ... before the market opens on Wednesday, August 5th, 2015. ... 2015, at 9:00 a.m. ET / 9:00 p.m. ... in the call, please dial the following numbers approximately 5 ...
(Date:7/24/2015)... ... July 24, 2015 , ... ... to any modern scientific or pharmaceutical laboratory. FreezerPro® is an intuitive, fast, ... precisely where a sample is located even before opening the freezer door! ...
(Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... Science and ... radiation, to new drug therapies and devices – according to Susan Chang, MD, director ... a session on how science and new technology are impacting the development of new ...
(Date:7/23/2015)... ... July 23, 2015 , ... July ... by providing more targeted treatment options with fewer side effects, according to Erik ... Anderson Cancer Center. , At the American Brain Tumor Association (ABTA) National Patient ...
Breaking Biology Technology:Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 2Experts Present How Science and New Technology are Driving New Brain Tumor Treatments and Improving Quality of Life 3Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 2Radiation Oncology Advances Improve Safety and Efficacy of Treatment for Brain Tumors 3
... Signal Genetics, the parent company of Myeloma Health, ... oncology, today announced the formation of their Scientific Advisory ... Director, Jerome Lipper Multiple Myeloma Center, ... Medicine, Harvard Medical School Dr. Anderson of ...
... Calif., Oct. 26 Telik, Inc. (Nasdaq: ... company,s lead therapeutic product candidate, has been selected by ... Top 10 Most Interesting Oncology Projects to Watch."  Windhover ... executives in the pharmaceutical, biotechnology, and medical device industries. ...
... Regado Biosciences, a privately held company leading the development ... David J. Mazzo, PhD, President and CEO, will be ... Mazzo,s presentation will be given at the Waldorf-Astoria Hotel ... at 10:45 a.m. EDT in the Louis XVI Room. ...
Cached Biology Technology:Signal Genetics Announces Establishment of Scientific Advisory Board 2Signal Genetics Announces Establishment of Scientific Advisory Board 3TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 2TELINTRA® Named One of the 10 Most Interesting Oncology Projects to Watch 3Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 2Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City 3
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/25/2015)... , June 25, 2015  Imagine a tool specifically ... a healthier, happier life. That,s exactly what USANA,s ... do. The cutting-edge, portable health program provides a personalized ... to help improve your lifestyle and nutrition. ... and gala Wednesday night, USANA,s THA was honored with ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Photosynthesis takes place in specialized membrane systems, made up ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich has now ... the edge of each stack. Scanning electron microscopy ... mays ) showing thylakoids (green) and assimilation starch granules ...
...  Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer ... products, has announced the issuance of two new U.S. ... of health data collected by point-of-care testing devices using ... a method and apparatus for manufacturing disposable dry test ...
... 2013 /PRNewswire-iReach/ -- Urologyweb.com, a leading website from Dr. ... outlining which prostate cancers really need treatment. ... favorable-risk Gleason 6 (3+3) prostate cancer and the ... not progress and do not need any treatment whether through ...
Cached Biology News:Photosynthesis: Membranes in tight corners 2PTS, Inc. Announces Two New Patents 2Which Prostate Cancers Really Need Treatment? 2Which Prostate Cancers Really Need Treatment? 3
Sphingosine 1-phosphate receptor Edg-1...
Bag-1 (K-20)...
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... LC-mass spectrometry. PGE2 is one of the ... one of the most widely investigated prostaglandins. ...
, Glycerol 30%...
Biology Products: